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ABSTRACT 
The last two decades have witnessed the increasing instrumentalization of viruses, which 
have progressively evolved into highly potent gene transfer vehicles for a wide spectrum of 
applications. In the context of the central nervous system (CNS), their unique gene delivery 
features and targeting specificities have been exploited not only to improve our 
understanding of basic neurobiology, but also to investigate diseases or deliver therapeutic 
candidates. As a result, we have started moving away from the opportunistic use of 
recombinant vectors that are derived from naturally existing viruses towards the rational 
engineering of tailored lentivirus (LV) and adeno-associated virus (AAV) vectors for specific 
use in the CNS.  
  
 
Keywords: VIRAL VECTORS, LENTIVRUS, ADENO-ASSOCIATED VIRUS, CNS, GENE THERAPY, 
NEURODEGENERATIVE DISEASE, TRANSGENE EXPRESSION 
 
  
 3 
 
Highlights 
• AAV and LV vectors for gene delivery in the central nervous system 
• Gene therapy as a major driver for viral vector development 
• Treatment of neurodegenerative diseases with gene therapies 
• Viral vector-based modeling of diseases in animals 
• Cell-type specific transgene expression  
• Drug-inducible and optogenetic switches for spatial and temporal gene 
expression 
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VIRAL VECTORS 
Virus-mediated gene delivery applications include fundamental neurobiological 
investigation [1], disease modeling [2], and gene therapy [3], each requiring a unique set 
of features: i.e. tropism, transduction efficiency, safety, and packaging capacity [4]. This 
has led to the investigation of more than a dozen viral species from various families [5]. 
Vectors derived from lentivirus and adeno-associated viruses are currently the most 
frequently used for rodent and primate CNS research and in gene therapy clinical trials 
[5,6].  
 
Adeno-associated viral (AAV) vectors  
AAVs are non-pathogenic, single stranded DNA viruses from the Dependovirus 
genus of the Parvoviridae that require helper virus infection for successful replication [7]. 
Viruses of this genus are non-enveloped and transduce dividing and non-dividing cells. A 
complete review of AAV biology is beyond the scope of this article but has been reviewed 
thoroughly elsewhere [8]. After transduction, the 4.7 kb viral genome remains 
predominantly episomal, providing long-term gene expression in non-dividing cells. The 
viral capsid is composed of three capsid proteins (VP1, VP2, and VP3) and the amino 
acids of the common VP region compose the protein domains that are exposed on the 
surface of the assembled capsid. They are responsible for surface topology and determine 
tropism and specificity [9]. Artificial AAV serotypes with new characteristics and tropisms 
have been produced by altering the cap genes [10]. The ease with which it is possible to 
alter AAV enables the development of large vector libraries (Figure 1) to screen and 
identify vectors with specific features that are tailored for specific applications [11].  
 
Lentiviral vectors (LV)  
Lentiviruses belong to the family of Retroviridae. The most extensively studied 
lentivirus is HIV-1 which possesses two copies of a positive sense RNA genome of 
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approximately 9 kb [12]. In contrast to gamma retroviruses, LV retroviruses have the 
unique ability to translocate across the nuclear membrane and infect non-dividing cells. 
The genome contains nine genes from which only the gag, pol, and rev genes are co-
expressed for viral vector production in HEK293T host cells [13,14]. In this system, all 
virulence factors have been deleted to generate non-pathogenic and replication-deficient 
LV vectors [14]. The envelope gene of HIV-1 is, in most cases, replaced by a heterologous 
gene to alter tropism and specificity [15]. The most commonly used envelope is the 
vesicular stomatitis virus glycoprotein (VSV-G). LVs pseudotyped with the VSV-G 
efficiently transduce neurons (Figure 1) and are highly mechanically resistant, facilitating 
their concentration and purification [14].  
 
APPLICATION OF AAV AND LV VECTORS FOR GENE THERAPY 
 
The field of gene therapy has been the major driver for the research and 
development of viral vector technologies. The efforts are reflected by the 2356 clinical 
trials that have been conducted to date. Only 43 of these trials have targeted brain 
diseases (February 2016, http://www.wiley.com/legacy/wileychi/genmed/clinical/). The low 
number of CNS trials relative to other indications (cancer or immunodeficiency) highlights 
the difficulty of vector delivery to the CNS but also our only partial understanding of these 
diseases. The blood-brain barrier (BBB) limits entry of molecules to the brain. Thus, 
vectors are delivered directly to their site of action, most commonly via intracranial or 
intrathecal injection. Specific viral vectors are capable of crossing the BBB, but 
intravenous injection exposes the vectors to circulating antibodies, leads to widespread 
transduction of various tissues, and therefore requires very high doses of vector [16-18].  
Due to the increased need of vectors for translating gene therapy applications into 
the clinic, the development of new protocols for viral vector production is becoming central 
as manufacturing protocols must be compliant with good manufacturing practice (GMP) 
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and suitable for the production and qualification of large batches. For a detailed review on 
this topic, please refer to the following publications [19,20]. 
 Most clinical trials for treatments of neurodegenerative diseases used AAV or LV 
vectors (http://www.wiley.com/legacy/wileychi/genmed/clinical/). This includes AAV gene 
therapy for Canavan disease, a pediatric leukodystrophy [21], Parkinson’s and Alzheimer’s 
disease [22] [23], AADC deficiency [24] , and LV gene therapy for X-linked 
Adrenoleukodystrophy [25] and Metachromatic Leukodystrophy [26]. For a detailed review 
on gene therapy and clinical trials, refer to Choudhury et al. [3]. The therapeutic effects 
observed for most early clinical trials were limited, but more recent trials have shown very 
encouraging results [27]. The demonstration of safety, including the absence adverse 
effects resulting from insertional mutagenesis, has been an important finding [28], in 
addition to the therapeutic outcome. These early studies with first generation vectors were 
definitely a milestone, but they have also highlighted shortcomings and challenges, which 
have to be addressed to create improved vectors for future applications [27].  
 
NEXT GENERATION OF VIRAL VECTOR-BASED GENE DELIVERY 
 
The tropism and transduction pattern of a vector depends on multiple parameters, 
including its diffusion properties, the expression of receptors on target cells, the affinity of 
capsid or envelope proteins for the receptors, and intracellular factors. LV has a diameter 
of 100 nm and the transduced area in the parenchyma is limited to a few millimeters [29], 
whereas the diffusion of AAV (20 nm diameter) is highly dependent on each serotype [30-
32]. Recent studies have focused on evaluating new AAV serotypes or pseudotyped LV 
vectors to identify the most potent vectors and take advantage of retrograde transport 
properties. Various AAV serotypes are capable of retrograde transport to distal neuronal 
projection sites (Figure 2) [33,34]. Retrograde transport of LV is obtained using specific 
envelopes of the Rhabdoviridae family [35,36] further increasing the versatility of these 
vectors in the CNS (Figure 1 and 2) (for comprehensive reviews see [12,37]).  
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Advances in vector technology are clearly critical for basic studies of the CNS as 
well as clinical development of therapeutic strategies, but other hurdles need to be 
overcome to fully translate basic research into the clinic. Applying vectors to targeting the 
brain in the CNS presents a considerable challenge regarding scale-up, as the human 
brain is approximately 3000 times larger than that of a mouse, the most commonly used 
animal model in research. This becomes especially problematic when the aim is to deliver 
the transgene to large regions of the CNS for therapies targeting Alzheimer’s disease, 
lysosomal storage disorders, or Parkinson’s disease [38]. Gene transfer via intra-
parenchymal injections translates into a large number of injection tracts due to a diffusion 
distance of millimeters to a few centimeters in the brain parenchyma [39]. Convection-
enhanced delivery of vectors to the brain parenchyma is one promising strategy to 
improve vector diffusion [40,41]. This technique has been frequently applied in studies on 
non-human primates [42] as well as recent clinical trials, and improves diffusion 
throughout the brain by maintaining the injection pressure at a level sufficient to overcome 
the hydrostatic pressure of the interstitial fluid [41,43].  
Intravascular (IV) administration may be a very attractive alternative strategy. IV 
injection is non-invasive and could allow transduction of the entire brain due to the high 
capillary density of the CNS [44]. Potential disadvantages of this approach are possible 
clearance by circulating antibodies and inefficient penetration of the CNS through the BBB 
[18]. A compromise between IV- and IC-based approaches is the administration of vectors 
into the cerebrospinal fluid (CSF), which maximizes CNS exposure [38]. Studies in non-
human primates have reported stronger transgene expression throughout the cortex and 
cerebellum after injection of an AAV9 vector into the cisterna magna relative to IV injection 
[18].  
A strategy that utilizes a therapeutic gene that is secreted from the transduced cells 
combined with the above-described methods for administration could result in highly 
pervasive distribution throughout the CNS for a global therapeutic effect [45]. Transduction 
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of ependymal cells lining the ventricles after CSF injection for the expression of a factor in 
the CNS is one example of how this strategy could be applied [45]. 
In contrast to strategies that aim for global delivery to the CNS and make use of 
ubiquitous promoters for high transgene expression, some clinical studies, as well as 
disease modeling and fundamental studies, require controlled transgene expression, 
limited to just one specific cell-type, to investigate its function within a complex neuronal 
network or its relevance in pathology (Figure 1 and 2). Current efforts use cell-type specific 
promoters, microRNA target (miRT) sequences, and highly specific vectors (Figure 2) 
[32,46,47]. The miRNA belongs to the group of non-coding RNAs, which play a 
fundamental role in processes such as chromatin remodeling, gene expression, and 
transcript processing. The international ENCODE Consortium is currently cataloging 
functional DNA elements in the human genome in various cell types and tissues to shed 
light on regulation of gene expression [48,49]. Insights from this line of research will 
ultimately make it possible to precisely control gene expression in target cells after viral 
vector transduction. Such control of gene expression is important for studying the basic 
biology of the CNS and also to increase the safety of future therapeutic applications [32]. 
Currently, inducible promoters, or a combination of cell-type specific promoters coupled 
with inducible elements, allow good spatial and temporal control of transgene expression 
[50]. Drawbacks of drug inducible systems are leakiness, induction kinetics, and immune 
responses which have precluded clinical implementation of these systems [51]. 
 Precise spatial and temporal resolutions are required to monitor neurobiological 
functions and to investigate synaptic connections of neuronal subpopulations in specific 
compartments of the CNS. Recent optogenetic approaches that couple viral vectors, light 
inducible proteins, and promoters specific for a neuronal phenotype are a powerful tool in 
neurosciences [52]. This approach allows precise spatial, temporal, and phenotype 
specific transgene expression after light induction at a given wavelength using optical 
fibers, and has been increasingly applied to CNS studies. 
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Altogether, the combination of the vector features, delivery strategies, neuronal 
circuitry, properties of the therapeutic candidates (secreted vs intracellular), and 
technologies to control transgene expression offer numerous opportunities for next 
generation gene delivery. 
 
PERSPECTIVES  
A viral vector toolkit with improved vectors that are tailored to specific applications 
is becoming increasingly realistic and is taking shape due to interdisciplinary research and 
the development of enabling technologies in the fields of virology, molecular biology, 
neurosciences, medicine, and engineering. Coupled with these new and powerful 
technologies, such as optogenetics and genome editing, viral vector based gene delivery 
will enable us to further increase our understanding of neurobiology. Furthermore, it 
facilitates the investigation of the molecular basis of pathologies and allows accurate 
modeling of neurological diseases. More refined viral vectors and transgenes will 
ultimately lead to a deeper understanding of the CNS and its diseases, which will allow the 
successful treatment, not only of neurodegenerative diseases, but also other indications 
associated with the CNS.  
 
 
Highlights 
• AAV and LV vectors for gene delivery in the central nervous system 
• Gene therapy as a major driver for viral vector development 
• Treatment of neurodegenerative diseases with gene therapies 
• Viral vector-based modeling of diseases in animals 
• Cell-type specific transgene expression  
• Next generation viral vector-based delivery 
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FIGURES  
 
 
Figure 1 
Cell-type specific targeting of CNS cells with various AAV serotypes and lentiviral 
vectors.  
The scheme illustrates the large collection of AAV and lentiviral vectors available for CNS 
applications. Transduction of subpopulations of cells is made possible (neurons, astrocytes, 
microglial cells, plexus choroïd, progenitor cells, etc.) by modifying the capsids (AAV) or 
envelopes (LV), or by integrating specific regulatory elements (promoter, microRNA-based 
detargeting strategies).  
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Figure 2 
Scheme illustrating how retrograde transport properties and specific regulatory 
elements could be used to maximize gene transfer and/or target specific 
subpopulations of neurons in the brain. 
 LV vectors peusdotyped with envelopes of the Rhabdoviridae family infect cells at the 
injection site and are retrogradely transported to distal projection sites. The scheme 
illustrates a scenario in which transgene expression is cell-type specific. After transport to 
the cortex (Projection site A), the transgene exhibits expression of the yellow marker, 
whereas the expression of the red marker is limited to neurons in the substancia nigra 
(Projection site B). 
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